Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancerMichal Mego, James M. Reuben, Hui Gao et al.|Oncotarget|2016Cited by 72
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancerLuca Licata, Giampaolo Bianchini, Mariana Chávez‐MacGregor et al.|npj Breast Cancer|2023Cited by 18
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysisRoberto Buonaiuto, Carmine De Angelis, Mario Fordellone et al.|EClinicalMedicine|2025Cited by 7
Abstract P1-16-01: Efficacy of endocrine- versus chemotherapy-based treatments in hormone receptor-positive (HR+ve), HER2-negative (HER2-ve) postmenopausal metastatic breast cancer (mBC): A network meta-analysis (NMA)Francesco Schettini, Daniele Generali, Mario Giuliano et al.|Cancer Research|2019Cited by 2
Correlation of circulating tumor cells (CTCs) with peripheral blood leukocytes to predict outcome in metastatic breast cancer (MBC).Ugo De Giorgi, James M. Reuben, Michal Mego et al.|Journal of Clinical Oncology|2016Cited by 2